{
  "id": "mhgap#risk_safety_5960c57c",
  "content": "in adults. There is low-quality evidence that\nthe outcomes.\nphenobarbital may be more effective than sodium\ny A staged treatment protocol for management of\nvalproate in the treatment of benzodiazepine-\nstatus epilepticus is recommended.\nresistant status epilepticus in adults.\ny There is low- to moderate-quality evidence that – Approximately 30–40% of all individuals fail to\nrespond to initial treatment with benzodiazepines\nthe safety profile of levetiracetam was better than\n(benzodiazepine-resistant or established status\nfosphenytoin, in terms of lesser cardiovascular\nepilepticus) and need further treatment with\nadverse events. There is low-quality evidence\nother intravenous antiseizure medicines (ASMs).\nthat phenobarbital has a higher risk of respiratory\nThe treatment of established status epilepticus is\ndepression and cardiovascular adverse effects as\nthe focus of this recommendation with the above\ncompared with sodium valproate.\nmedicines initiated when seizures persist after\ny Another factor of concern is the speed of\ntwo doses of benzodiazepines.\nadministration. Fosphenytoin, levetiracetam and\ny Advantages of levetiracetam and sodium valproate\nsodium valproate can be administered within 10\ninclude lesser risk of adverse effects as compared\nminutes, whereas phenobarbital and phenytoin\nwith fosphenytoin. Both levetiracetam and sodium\nneed to be infused over 20 minutes. Time is of the",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety in adults. There is low-quality evidence that\nthe outcomes.\nphenobarbital may be more effective than sodium\ny A staged treatment protocol for management of\nvalproate in the treatment of benzodiazepine-\nstatus epilepticus is recommended.\nresistant status epilepticus in adults.\ny There is low- to moderate-quality evidence that – Approximately 30–40% of all individuals fail to\nrespond to initial treatment with benzodiazepines\nthe safety profile of levetiracetam was better than\n(benzodiazepine-resistant or established status\nfosphenytoin, in terms of lesser cardiovascular\nepilepticus) and need further treatment with\nadverse events. There is low-quality evidence\nother intravenous antiseizure medicines (ASMs).\nthat phenobarbital has a higher risk of respiratory\nThe treatment of established status epilepticus is\ndepression and cardiovascular adverse effects as\nthe focus of this recommendation with the above\ncompared with sodium valproate.\nmedicines initiated when seizures persist after\ny Another factor of concern is the speed of\ntwo doses of benzodiazepines.\nadministration. Fosphenytoin, levetiracetam and\ny Advantages of levetiracetam and sodium valproate\nsodium valproate can be administered within 10\ninclude lesser risk of adverse effects as compared\nminutes, whereas phenobarbital and phenytoin\nwith fosphenytoin. Both levetiracetam and sodium\nneed to be infused over 20 minutes. Time is of the In adults. there is low-quality evidence that\nthe outcomes."
}